Fatty liver disease
The worldwide increase in obesity and diabetes has led to a spike in non-alcoholic fatty liver disease, which often progresses to the more severe condition non-alcoholic steatohepatitis. This Outlook discusses topics such as the surge in drug development that is poised to deliver new treatments; how innovative technologies are enabling earlier diagnosis; and the disturbing rise of fatty liver disease in children.
This Nature Outlook is editorially independent. It is produced with third party financial support. About this content.
Nature is pleased to acknowledge the financial support of Gilead Sciences in producing this Outlook. The sponsor retains sole responsibility for the following messages.
For 30 years, Gilead has worked to develop medicines that address areas of unmet medical need for people around the world.
Gilead’s medicines and pipeline of investigational drugs include treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
